Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

Agnieszka K. Witkiewicz, Sejin Chung, Rachel Brough, Paris Vail, Jorge Franco, Christopher J. Lord, Erik S. Knudsen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Approximately 30% of triple-negative breast cancers (TNBCs) exhibit functional loss of the RB tumor suppressor, suggesting a target for precision intervention. Here, we use drug screens to identify agents specifically antagonized by the retinoblastoma tumor suppressor (RB) using CDK4/6 inhibitors. A number of candidate RB-synthetic lethal small molecules were identified, including anti-helmenthics, chemotherapeutic agents, and small-molecule inhibitors targeting DNA-damage checkpoints (e.g., CHK) and chromosome segregation (e.g., PLK1). Counter-screens using isogenic TNBC tumor cell lines and cell panels with varying endogenous RB statuses confirmed that therapeutic effects were robust and selective for RB loss of function. By analyzing TNBC clinical specimens, RB-deficient tumors were found to express high levels of CHK1 and PLK1. Loss of RB specifically resulted in loss of checkpoint functions governing DNA replication, yielding increased drug sensitivity. Xenograft models demonstrated RB-selective efficacy of CHK inhibitors. This study supports the possibility of selectively targeting RB loss in the treatment of TNBC. Witkiewicz et al. demonstrate that the activation state of the RB tumor suppressor is a critical determinant for selected targeted therapies in models of TNBC. Loss of RB yields a selective vulnerability to replication and chromosome segregation stress. Drugs targeting CHK and PLK have increased efficacy in RB-deficient tumors.

Original languageEnglish (US)
Pages (from-to)1185-1199
Number of pages15
JournalCell Reports
Volume22
Issue number5
DOIs
StatePublished - Jan 30 2018

Fingerprint

Triple Negative Breast Neoplasms
Tumors
Chromosome Segregation
Neoplasms
Chromosomes
Retinoblastoma
Therapeutic Uses
Drug Delivery Systems
Tumor Cell Line
Molecules
DNA Replication
Heterografts
Pharmaceutical Preparations
DNA
DNA Damage
Breast Neoplasms
Chemical activation
Cells
Therapeutics

Keywords

  • CDK4
  • chemotherapy
  • CHK1
  • cyclin
  • E2F
  • palbociclib
  • PLK1
  • RB
  • retinoblastoma
  • ribociclib

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. / Witkiewicz, Agnieszka K.; Chung, Sejin; Brough, Rachel; Vail, Paris; Franco, Jorge; Lord, Christopher J.; Knudsen, Erik S.

In: Cell Reports, Vol. 22, No. 5, 30.01.2018, p. 1185-1199.

Research output: Contribution to journalArticle

Witkiewicz, AK, Chung, S, Brough, R, Vail, P, Franco, J, Lord, CJ & Knudsen, ES 2018, 'Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer', Cell Reports, vol. 22, no. 5, pp. 1185-1199. https://doi.org/10.1016/j.celrep.2018.01.022
Witkiewicz, Agnieszka K. ; Chung, Sejin ; Brough, Rachel ; Vail, Paris ; Franco, Jorge ; Lord, Christopher J. ; Knudsen, Erik S. / Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. In: Cell Reports. 2018 ; Vol. 22, No. 5. pp. 1185-1199.
@article{9aade3decc654e9eb439ac320d1d2cb4,
title = "Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer",
abstract = "Approximately 30{\%} of triple-negative breast cancers (TNBCs) exhibit functional loss of the RB tumor suppressor, suggesting a target for precision intervention. Here, we use drug screens to identify agents specifically antagonized by the retinoblastoma tumor suppressor (RB) using CDK4/6 inhibitors. A number of candidate RB-synthetic lethal small molecules were identified, including anti-helmenthics, chemotherapeutic agents, and small-molecule inhibitors targeting DNA-damage checkpoints (e.g., CHK) and chromosome segregation (e.g., PLK1). Counter-screens using isogenic TNBC tumor cell lines and cell panels with varying endogenous RB statuses confirmed that therapeutic effects were robust and selective for RB loss of function. By analyzing TNBC clinical specimens, RB-deficient tumors were found to express high levels of CHK1 and PLK1. Loss of RB specifically resulted in loss of checkpoint functions governing DNA replication, yielding increased drug sensitivity. Xenograft models demonstrated RB-selective efficacy of CHK inhibitors. This study supports the possibility of selectively targeting RB loss in the treatment of TNBC. Witkiewicz et al. demonstrate that the activation state of the RB tumor suppressor is a critical determinant for selected targeted therapies in models of TNBC. Loss of RB yields a selective vulnerability to replication and chromosome segregation stress. Drugs targeting CHK and PLK have increased efficacy in RB-deficient tumors.",
keywords = "CDK4, chemotherapy, CHK1, cyclin, E2F, palbociclib, PLK1, RB, retinoblastoma, ribociclib",
author = "Witkiewicz, {Agnieszka K.} and Sejin Chung and Rachel Brough and Paris Vail and Jorge Franco and Lord, {Christopher J.} and Knudsen, {Erik S.}",
year = "2018",
month = "1",
day = "30",
doi = "10.1016/j.celrep.2018.01.022",
language = "English (US)",
volume = "22",
pages = "1185--1199",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

AU - Witkiewicz, Agnieszka K.

AU - Chung, Sejin

AU - Brough, Rachel

AU - Vail, Paris

AU - Franco, Jorge

AU - Lord, Christopher J.

AU - Knudsen, Erik S.

PY - 2018/1/30

Y1 - 2018/1/30

N2 - Approximately 30% of triple-negative breast cancers (TNBCs) exhibit functional loss of the RB tumor suppressor, suggesting a target for precision intervention. Here, we use drug screens to identify agents specifically antagonized by the retinoblastoma tumor suppressor (RB) using CDK4/6 inhibitors. A number of candidate RB-synthetic lethal small molecules were identified, including anti-helmenthics, chemotherapeutic agents, and small-molecule inhibitors targeting DNA-damage checkpoints (e.g., CHK) and chromosome segregation (e.g., PLK1). Counter-screens using isogenic TNBC tumor cell lines and cell panels with varying endogenous RB statuses confirmed that therapeutic effects were robust and selective for RB loss of function. By analyzing TNBC clinical specimens, RB-deficient tumors were found to express high levels of CHK1 and PLK1. Loss of RB specifically resulted in loss of checkpoint functions governing DNA replication, yielding increased drug sensitivity. Xenograft models demonstrated RB-selective efficacy of CHK inhibitors. This study supports the possibility of selectively targeting RB loss in the treatment of TNBC. Witkiewicz et al. demonstrate that the activation state of the RB tumor suppressor is a critical determinant for selected targeted therapies in models of TNBC. Loss of RB yields a selective vulnerability to replication and chromosome segregation stress. Drugs targeting CHK and PLK have increased efficacy in RB-deficient tumors.

AB - Approximately 30% of triple-negative breast cancers (TNBCs) exhibit functional loss of the RB tumor suppressor, suggesting a target for precision intervention. Here, we use drug screens to identify agents specifically antagonized by the retinoblastoma tumor suppressor (RB) using CDK4/6 inhibitors. A number of candidate RB-synthetic lethal small molecules were identified, including anti-helmenthics, chemotherapeutic agents, and small-molecule inhibitors targeting DNA-damage checkpoints (e.g., CHK) and chromosome segregation (e.g., PLK1). Counter-screens using isogenic TNBC tumor cell lines and cell panels with varying endogenous RB statuses confirmed that therapeutic effects were robust and selective for RB loss of function. By analyzing TNBC clinical specimens, RB-deficient tumors were found to express high levels of CHK1 and PLK1. Loss of RB specifically resulted in loss of checkpoint functions governing DNA replication, yielding increased drug sensitivity. Xenograft models demonstrated RB-selective efficacy of CHK inhibitors. This study supports the possibility of selectively targeting RB loss in the treatment of TNBC. Witkiewicz et al. demonstrate that the activation state of the RB tumor suppressor is a critical determinant for selected targeted therapies in models of TNBC. Loss of RB yields a selective vulnerability to replication and chromosome segregation stress. Drugs targeting CHK and PLK have increased efficacy in RB-deficient tumors.

KW - CDK4

KW - chemotherapy

KW - CHK1

KW - cyclin

KW - E2F

KW - palbociclib

KW - PLK1

KW - RB

KW - retinoblastoma

KW - ribociclib

UR - http://www.scopus.com/inward/record.url?scp=85044871687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044871687&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2018.01.022

DO - 10.1016/j.celrep.2018.01.022

M3 - Article

C2 - 29386107

AN - SCOPUS:85044871687

VL - 22

SP - 1185

EP - 1199

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 5

ER -